Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Approval Received for Phase II Trial of ATL1102 in Duchenne Muscular Dystrophy

2018-02-28 accesswire
MELBOURNE, AUSTRALIA / ACCESSWIRE / February 28, 2018 / Antisense Therapeutics ("ANP" or the "Company") (ASX: ANP; OTC PINK: ATHJF) is pleased to advise that the Company has received approval from the Royal Children's Hospital (RCH), Melbourne Human Research Ethics Committee, to undertake a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD), an incurable muscle-wasting disease of children. (38-0)

Prostate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals Inc and Advaxis Inc, Says a New Research Report at

2017-07-11 prnewswire
Prostate Cancer Pipeline Review, H1 2017 is new research report highlights details analysis includes 1845 pages with latest updates, Drug Profiles, Key players, Table of Contents, List of Tables, List of Figures. (0-2)

Antisense Therapeutics to commence muscular dystrophy trials

Antisense Therapeutics (ASX:ANP) is planning to undertake a clinical trial of its immunomodulatory therapy ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).

Pipeline of Asthma Market Covering 129 Companies Reviewed for H1 2016 in New Research Report

2016-05-31 prnewswire adds "Asthma - Pipeline Review, H1 2016" market research report with comparative analysis of Asthma therapy at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.

Appendix 4C - quarterly


Antisense Therapeutics Limited in ASX trading halt

Antisense Therapeutics Limited is preparing to outline details in relation to the ATL1103 program for multiple sclerosis

COR-004/ATL1103 Project Update


Trading Halt


Trading Halt Request


Half Yearly Report and Accounts


Company Update


Appendix 4C - quarterly